Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 71.3%

Neg 0% Neu 0% Pos 71.3%

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $20 to $32.